"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition ...

Neurocrine Biosciences, Inc. today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an ...

Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...

"The significant improvements observed in AIMS score and the high remission rates highlight the efficacy of INGREZZA, at even the lowest dose." The post-hoc analysis was conducted using data from ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine). Post-hoc ...